Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1771)	4/18/2007 12:13:20 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

CPHD Is up 11.35% after it said that the FDA approved its test that quickly detects staphs that are Methicillin-resistant. MRSA is one of the leading causes of nosocomial infections, including serious skin infections, generalized sepsis, pneumonia & death. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1771)	8/23/2007 5:28:08 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

RGEN was up 7% & closed at its intraday H. bigcharts.marketwatch.com The stock was able to close above its Aug 13 H & it seems ready to test its March 2006 H at 4.59 bigcharts.marketwatch.com In April it acquired the rights to intellectual property that cover compounds which may be useful in treating Friedreich's ataxia. It has completed enrollment in the PII of RG2417 for bipolar depression and expects to have results before year's end. In May, it reported positive results from a PII of RG1068 as an agent to improve visualization of pancreatic ducts by MRI). In the 1stQ revenues improved 65% to $5,978,000 compared to the results in the 20067 fiscal Yr.(It has had 3 consecutive Qs of double digit improvement on revenues.) The lawsuit that it filed together with MIT against IMCL for infringement of a patent which IMCL uses to make Erbitux is scheduled for a jury trial on Sep 10 in Boston.(RGEN alleges that the cell line that IMCL uses employs a key technology claimed in the patent.) The other lawsuit against BMY concerns a method of treating RA with CTLA4-Ig.(RGEN licensed the rights to a U.S. patent owned by University of Michigan that covers a method of treating RA with CTLA4-Ig that remains in force until 2021.}BMY received approval from the FDA to market CTLA4-Ig for treatment of RA, under the name of Orencia.The trial on this lawsuit is scheduled for April 2008. (Sales of Orencia are expected to reach annual sales of $1B.)(I think this is the lawsuit in which Peter was interested at one time.<g>) RGEN has no significant LTD. Its cash as of Jun30 reportedly was $21.816M, compared with $22.627M as of Mar31.(There are 30.62M shares out.) Bernard